Tanshinone IIA potentiates the chemotherapeutic effect of doxorubicin against breast cancer cells and attenuates the cardiotoxicity of doxorubicin by regulating ERK1/2 pathway
Journal of Biochemical and Molecular Toxicology · 2024
DOI: 10.1002/jbt.23851 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Biochemical and Molecular Toxicology, 2024. Verfasst von Shizheng Li und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Emergency Surgery, The First Affiliated Hospital of Jinzhou Medical University, Jinzhou, China. Hauptthemen laut MEDLINE: Doxorubicin, Abietanes, Breast Neoplasms, MAP Kinase Signaling System. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 26 Literaturangaben. Gefördert von: The Natural Science Foundation of Liaoning Province, The Scientific Research Foundation of The First Affiliated Hospital of Jinzhou Medical.
Abstract (Originalsprache)
Doxorubicin (Dox) is frequently employed as a chemotherapy agent for breast cancer. As the chemotherapy moves forward, breast cancer cells tend to develop resistance to Dox, besides that, Dox are also easy to cause cardiotoxicity related to cumulative dose. Therefore, how to potentiate the chemosensitivity of breast cancer cells to Dox while attenuating its cardiotoxicity has become a research hotspot. Tanshinone IIA (Tan IIA) is known for its anticancer activity as well as for its cardioprotective effects. In view of the aforementioned facts, we assessed whether Tan IIA possesses synergism and attenuation effect on Dox for breast cancer chemotherapy. Our studies in vitro indicated that, Tan IIA could potentiate the effect of Dox on breast cancer cells proliferation inhibition and apoptosis promotion by inhibiting ERK1/2 pathway, but interestingly, Tan IIA attenuated the cytotoxicity of Dox to myocardial cells by activating ERK1/2 pathway. Additionally, our studies in vivo also suggested that Tan IIA potentiated the chemotherapeutic effect of Dox against breast cancer while attenuating Dox‐induced myocardial injury. Given that Tan IIA had a synergism and attenuation effect on Dox, we believed that Tan IIA can be used as an ideal drug in combination with Dox for breast cancer therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Emergency Surgery, The First Affiliated Hospital of Jinzhou Medical University, Jinzhou, China.
- Department of Clinical Laboratory, The First Affiliated Hospital of Jinzhou Medical University, Jinzhou, China.
- Department of Clinical Laboratory, Jinzhou Women and Children's Hospital, Jinzhou, China.
Förderung
- The Natural Science Foundation of Liaoning Province
- The Scientific Research Foundation of The First Affiliated Hospital of Jinzhou Medical
Zitieren
APA
Li, S., FeiyuTeng, Zhang, J., Zhang, P., Li, M., Wang, X., & Li, K. (2024). Tanshinone IIA potentiates the chemotherapeutic effect of doxorubicin against breast cancer cells and attenuates the cardiotoxicity of doxorubicin by regulating ERK1/2 pathway. Journal of Biochemical and Molecular Toxicology. https://doi.org/10.1002/jbt.23851
Vancouver
Li S, FeiyuTeng, Zhang J, Zhang P, Li M, Wang X, et al. Tanshinone IIA potentiates the chemotherapeutic effect of doxorubicin against breast cancer cells and attenuates the cardiotoxicity of doxorubicin by regulating ERK1/2 pathway. Journal of Biochemical and Molecular Toxicology. 2024. doi:10.1002/jbt.23851
BibTeX
@article{Li2024,
author = {Li, Shizheng and FeiyuTeng and Zhang, Jianing and Zhang, Puwei and Li, Manyuan and Wang, Xuezhe and Li, Kun},
title = {Tanshinone IIA potentiates the chemotherapeutic effect of doxorubicin against breast cancer cells and attenuates the cardiotoxicity of doxorubicin by regulating ERK1/2 pathway},
journal = {Journal of Biochemical and Molecular Toxicology},
year = {2024},
doi = {10.1002/jbt.23851}
}
EUVIMED